Finance

Lists
Outlook: 95.0% bullish·0.0% bearish
Go to analysis
ONC:NASDAQ
BeOne Medicines AG
$420.49
-0.83%
(-3.51) 1D
Nov 10, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ONC...
High
$420.99
Mkt. cap
50.08B
Avg. vol.
434.46K
Volume
23.36K
52-wk high
$420.99
Beta
0.63
Shares outstanding
109.79M
No. of employees
12K
High
$420.99
Mkt. cap
50.08B
Avg. vol.
434.46K
Volume
23.36K
52-wk high
$420.99
Beta
0.63
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeonemedicines.com
Analyst ratings
Based on 12 analysts giving stock ratings to ONC in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ONC in the last 3 months.
Highest
Current $420.49
$500.84 (+19.11%)
Average
$459.12 (+9.19%)
Lowest
$430.00 (+2.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jill Wu
CMB International Securities
Buy
Maintained
$468.62
+11.4%
11/06/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
$500.84
+19.1%
11/06/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$465.00
+10.6%
11/05/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$430.00
+2.3%
11/05/2026
Yaron Werber
TD Cowen
Buy
Maintained
$477.00
+13.4%
11/06/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$435.00
+3.5%
11/06/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$465.00
+10.6%
11/06/2026
Gregory Renza
Truist Financial
Buy
Reiterated
$448.00
+6.5%
11/06/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$463.00
+10.1%
11/06/2026
Etzer Darout
Barclays
Buy
Maintained
$446.00
+6.1%
11/06/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$466.00
+10.8%
10/19/2026
Derek Archila
Wells Fargo
Buy
Maintained
$400.00
-4.9%
10/16/2026
Jessica Fye
J.P. Morgan
Buy
Maintained
$445.00
+5.8%
10/01/2026
Kalpit Patel
Wolfe Research
Buy
Reiterated
$370.00
-12%
08/09/2026
David Li
Bank of America Securities
Buy
Reiterated
$423.00
+0.6%
08/06/2026
Faisal Khurshid
Jefferies
Buy
Upgraded
$380.00
-9.6%
07/12/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$415.00
-1.3%
05/20/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$367.00
-12.7%
05/15/2026
Rebecca Liang
Bernstein
Buy
Maintained
$412.00
-2%
03/18/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$3.28 / $1.88
+74.28%beat
Revenue / Est. (USD)
1.89B / 1.76B
+7.49%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.50B
1.51B
1.71B
1.89B
Cost of goods sold
142.42M
167.22M
174.53M
216.90M
Cost of revenue
142.42M
167.22M
174.53M
216.90M
Research and development expenses
615.42M
541.22M
612.28M
660.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
555.29M
555.10M
593.21M
593.46M
Operating expense
1.17B
1.10B
1.21B
1.25B
Total operating expenses
1.31B
1.26B
1.38B
1.47B
Operating income
185.04M
249.90M
325.05M
418.68M
Other non operating income
4.16M
14.54M
-2.68M
1.09M
EBT including unusual items
149.24M
259.22M
312.46M
410.36M
EBT excluding unusual items
189.96M
259.22M
309.33M
410.34M
Income tax expense
82.74M
31.86M
75.45M
25.65M
Effective tax rate
55.44%
12.29%
24.15%
6.25%
Other operating expenses
-
-
-
-
Net income
66.50M
227.36M
237.01M
384.71M
Net profit margin
4.44%
15.02%
13.90%
20.36%
Earnings per share
0.58
1.96
2.05
-
Interest and investment income
32.37M
27.66M
27.90M
33.66M
Interest expense
-32.47M
-32.89M
-39.74M
-42.41M
Net interest expenses
-103.00K
-5.22M
-11.84M
-8.74M
Depreciation and amortization charges
-
-
-
-
EBITDA
219.47M
289.30M
363.97M
456.01M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps